NCT05427383View on ClinicalTrials.gov

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Stomach Cancer
Interventions
DRUG

KN026/Placbo Injection

IV KN026/Placebo at 30 mg/kg on D1, Q3W

DRUG

Paclitaxel Injection

IV Paclitaxel at 175 mg/m² on D1, Q3W

DRUG

Docetaxel Injection

IV Docetaxel at 75 mg/m² on D1, Q3W

DRUG

Irinotecan Injection

IV Irinotecan at 125 mg/m² on D1, D8, Q3W

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY